Bill Text: TX HB3188 | 2023-2024 | 88th Legislature | Introduced
Bill Title: Relating to health benefit plan coverage for certain biomarker testing.
Spectrum: Slight Partisan Bill (Republican 5-2)
Status: (Introduced - Dead) 2023-04-18 - Left pending in committee [HB3188 Detail]
Download: Texas-2023-HB3188-Introduced.html
88R7022 RDS-F | ||
By: Bonnen | H.B. No. 3188 |
|
||
|
||
relating to health benefit plan coverage for certain biomarker | ||
testing. | ||
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: | ||
SECTION 1. Subtitle E, Title 8, Insurance Code, is amended | ||
by adding Chapter 1372 to read as follows: | ||
CHAPTER 1372. COVERAGE FOR BIOMARKER TESTING | ||
Sec. 1372.001. DEFINITIONS. In this chapter: | ||
(1) "Biomarker" means a characteristic that is | ||
objectively measured and evaluated as an indicator of normal | ||
biological processes, pathogenic processes, or pharmacologic | ||
responses to a specific therapeutic intervention. The term | ||
includes: | ||
(A) gene mutations; and | ||
(B) protein expression. | ||
(2) "Biomarker testing" means the analysis of a | ||
patient's tissue, blood, or other biospecimen for the presence of a | ||
biomarker. The term includes: | ||
(A) single-analyte tests; | ||
(B) multiplex panel tests; and | ||
(C) whole genome sequencing. | ||
(3) "Consensus statements" means statements that: | ||
(A) address specific clinical circumstances | ||
based on the best available evidence for the purpose of optimizing | ||
clinical care outcomes; and | ||
(B) are developed by an independent, | ||
multidisciplinary panel of experts that uses a transparent | ||
methodology and reporting structure and is subject to a conflict of | ||
interest policy. | ||
(4) "Nationally recognized clinical practice | ||
guidelines" means evidence-based clinical practice guidelines | ||
that: | ||
(A) establish a standard of care informed by a | ||
systematic review of evidence and an assessment of the benefits and | ||
costs of alternative care options; | ||
(B) include recommendations intended to optimize | ||
patient care; and | ||
(C) are developed by an independent organization | ||
or medical professional society that uses a transparent methodology | ||
and reporting structure and is subject to a conflict of interest | ||
policy. | ||
Sec. 1372.002. APPLICABILITY OF CHAPTER. (a) This chapter | ||
applies only to a health benefit plan that provides benefits for | ||
medical or surgical expenses incurred as a result of a health | ||
condition, accident, or sickness, including an individual, group, | ||
blanket, or franchise insurance policy or insurance agreement, a | ||
group hospital service contract, or an individual or group evidence | ||
of coverage or similar coverage document that is offered by: | ||
(1) an insurance company; | ||
(2) a group hospital service corporation operating | ||
under Chapter 842; | ||
(3) a health maintenance organization operating under | ||
Chapter 843; | ||
(4) an approved nonprofit health corporation that | ||
holds a certificate of authority under Chapter 844; | ||
(5) a multiple employer welfare arrangement that holds | ||
a certificate of authority under Chapter 846; | ||
(6) a stipulated premium company operating under | ||
Chapter 884; | ||
(7) a fraternal benefit society operating under | ||
Chapter 885; | ||
(8) a Lloyd's plan operating under Chapter 941; or | ||
(9) an exchange operating under Chapter 942. | ||
(b) Notwithstanding any other law, this chapter applies to: | ||
(1) a small employer health benefit plan subject to | ||
Chapter 1501, including coverage provided through a health group | ||
cooperative under Subchapter B of that chapter; | ||
(2) a standard health benefit plan issued under | ||
Chapter 1507; | ||
(3) a basic coverage plan under Chapter 1551; | ||
(4) a basic plan under Chapter 1575; | ||
(5) a primary care coverage plan under Chapter 1579; | ||
(6) a plan providing basic coverage under Chapter | ||
1601; | ||
(7) health benefits provided by or through a church | ||
benefits board under Subchapter I, Chapter 22, Business | ||
Organizations Code; | ||
(8) the state Medicaid program, including the Medicaid | ||
managed care program operated under Chapter 533, Government Code; | ||
(9) the child health plan program under Chapter 62, | ||
Health and Safety Code; | ||
(10) a regional or local health care program operated | ||
under Section 75.104, Health and Safety Code; | ||
(11) a self-funded health benefit plan sponsored by a | ||
professional employer organization under Chapter 91, Labor Code; | ||
(12) county employee group health benefits provided | ||
under Chapter 157, Local Government Code; and | ||
(13) health and accident coverage provided by a risk | ||
pool created under Chapter 172, Local Government Code. | ||
Sec. 1372.003. COVERAGE REQUIRED. (a) Subject to | ||
Subsection (b), a health benefit plan must provide coverage for | ||
biomarker testing for the purpose of diagnosis, treatment, | ||
appropriate management, or ongoing monitoring of an enrollee's | ||
disease or condition to guide treatment when the test is supported | ||
by medical and scientific evidence, including: | ||
(1) a labeled indication for a test approved or | ||
cleared by the United States Food and Drug Administration; | ||
(2) an indicated test for a drug approved by the United | ||
States Food and Drug Administration; | ||
(3) a national coverage determination made by the | ||
Centers for Medicare and Medicaid Services or a local coverage | ||
determination made by a Medicare administrative contractor; | ||
(4) nationally recognized clinical practice | ||
guidelines; or | ||
(5) consensus statements. | ||
(b) A health benefit plan issuer must provide coverage under | ||
Subsection (a) only when use of biomarker testing provides clinical | ||
utility because use of the test for the condition: | ||
(1) is evidence-based; | ||
(2) is scientifically valid; | ||
(3) is outcome focused; and | ||
(4) predominately addresses the acute issue for which | ||
the test is being ordered, except that a test may include some | ||
information that cannot be immediately used in the formulation of a | ||
clinical decision. | ||
(c) A health benefit plan must provide coverage under | ||
Subsection (a) in a manner that limits disruptions in care, | ||
including limiting the number of biopsies and biospecimen samples. | ||
SECTION 2. If before implementing any provision of this Act | ||
a state agency determines that a waiver or authorization from a | ||
federal agency is necessary for implementation of that provision, | ||
the agency affected by the provision shall request the waiver or | ||
authorization and may delay implementing that provision until the | ||
waiver or authorization is granted. | ||
SECTION 3. The change in law made by this Act applies only | ||
to a health benefit plan that is delivered, issued for delivery, or | ||
renewed on or after January 1, 2024. | ||
SECTION 4. This Act takes effect September 1, 2023. |